Abizista Tablets
PDF Leaflet Revision Date: 02 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of high-risk metastatic prostate cancer and metastatic castration-resistant prostate cancer.
Dosage (summary)
1 g once daily with 5 mg prednisone for mHNPC/mHSPC or 10 mg for mCRPC.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may harm a developing fetus.
Key Drug Interactions
- Strong CYP3A4 inducers
- Concomitant use with rifampicin
- Corticosteroids
Contraindications
- Hypersensitivity to abiraterone acetate
- Moderate to severe hepatic impairment
- Pregnancy
- Women
Common side effects
- Peripheral oedema
- Hypokalaemia
- Hypertension
- Urinary tract infection
- Increased liver enzymes
Counselling Points
- Take on an empty stomach
- Monitor blood pressure and liver function
- Use contraception during treatment
Serious warnings
- Hypertension
- Hepatotoxicity
- Cardiac failure risk
Important Disclaimer
The Abizista Tablets professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
